Full Press Release Details
NUTRIBAND INC. ACQUIRES 4P THERAPEUTICS
Orlando, Fla. - April 10, 2018 - Nutriband Inc.
(OTC: NTRB), a Nevada Corporation, is pleased to announce the acquisition of 4P Therapeutics Inc. on April 5, 2018.
Nutriband has acquired 100% interest in 4P Therapeutics for
a total of $1,900,000 payable in both company stock and cash. 4P Therapeutics will receive 250,000 shares of common stock and a
cash amount of $400,000. Steve Damon, CEO of 4P Therapeutics, has been appointed to the Nutriband Inc. Board of Directors.
4P Therapeutics will now become the Pharmaceutical and Development
arm of Nutriband Inc. with a specific focus on Transdermal and Topical Technologies, prescription drugs and clinical development.
Included in the acquisition of 4P's IP Portfolio is Defent
abuse deterrent patch technology, an opioid abuse deterrent platform for the transdermal
delivery of opioid-based medications. Defent lowers the risk of abuse and misuse, creating a safer treatment for patients.
Nutriband has also acquired 4P's
Exenatide transdermal delivery system, currently in Phase I clinical development. If successfully taken through Phase III and to
commercialization, it will compete with injectable Exenatide such as Byetta
by providing an injection free alternative for patients with type II diabetes.
A Full Pipeline of drugs and technology can be found on 4P's
website http://www.4ptherapeutics.com/.
4P Therapeutics is a private company focused on the research
and development of novel drug delivery technologies and therapeutics. 4P develops products that meet the needs of patients, physicians
and payers. The company has capabilities for developing pharmaceutical products ranging from pre-clinical testing to clinical manufacturing
and early stage clinical development (Phase I/II). A key company focus and area of expertise is in the development of transdermal
products for currently injected compounds, including proteins, peptides, macromolecules and biologics. Transdermal delivery of
commercially available drugs or biologics that are typically delivered via injection has the potential to improve safety, efficacy
and therapeutic outcomes associated with these treatments.
Nutriband Inc. appointed Steven Damon
to its Board of Directors. Steven Damon has over 30 years of experience with various business roles
in the medical and pharmaceutical industries. He is the founder and CEO of 4P Therapeutics, an Atlanta based transdermal drug delivery
company established in 2011. Steven also maintains an executive leadership role as Vice President for Business and Commercial Development
with Femasys an Atlanta based women's health care medtech company. In addition, he serves on the boards of Micron Biomedical,
Carmel Bioscience, Temple Therapeutics and Georgia BIO. He actively consults with various companies on strategy, financing and
Therapeutics, Steven led the Business Development team at Atlanta based Altea Therapeutics as the company's Senior Vice President
of Business Development. He founded and was President of Absorbable Polymers International a Birmingham, Alabama company.
He was an Executive Director at DURECT Corporation in Cupertino California where he led Business Development activities and was
responsible for the ALZET research drug delivery pump business. Steve started his life science career with Kimberly-Clark
Healthcare (now Halyard Healthcare) with lead responsibilities for commercial development of the healthcare business in Europe
and the acquisitions of a number of life science companies and products.
Additional activities
include industry related speaking engagements, publications and committee participation. Steven has been a long time mentor for
the Emory and Georgia Tech Ti:GER program and also participates in other GT student mentoring programs.
Nutriband Inc. appointed Alan Smith Ph.D. as Head of Regulatory
and Clinical Operations. Alan Smith, Ph.D., co-founded 4P Therapeutics in 2011 and serves as Vice President, Clinical, Regulatory,
Quality, and Operations. Previously, he was with Altea Therapeutics, most recently serving as Vice President, Product Development
and Head of Clinical R&D, Regulatory Affairs, and Project Management. At Altea, he led major research and development programs
with pharmaceutical companies such as Eli Lilly, Amylin, Hospira, Elan, and Novartis. He joined Altea as one of the first employees
and spent 12 years growing its multidisciplinary drug delivery research and development organization.
Dr. Smith has 20 years of experience in the research and development of drug and biologic delivery systems, diagnostics and medical
devices for treatment and management of diabetes, chronic pain and cardiovascular disease. Prior to joining Altea Therapeutics,
he led the development of transdermal glucose monitoring systems at SpectRx, Inc., a publicly traded noninvasive diagnostics company.
Dr. Smith received Ph.D. and M.S. degrees in Biomedical Engineering from Rutgers University and the University of Medicine and
Dentistry of New Jersey. He currently serves on the Editorial Advisory Board of Expert Opinion on Drug Delivery.
Nutriband is a unique, result's driven, health and pharmaceutical
Company based in Orlando Florida. Unlike traditional health product companies, Nutriband found its start by spotting and
targeting a gross and virtually unexplored niche in the market through its method of ingredient delivery. All Nutriband products
are based around the science of transdermal / Topical technologies.
About Our Forward-Looking Statements
Certain statements contained in this press release, including,
without limitation, statements containing the words "believes", "anticipates", "expects" and
words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. Our actual results
may differ materially from those anticipated in our forward-looking statements as a result of a number of factors, including our
ability to create, sustain, manage or forecast our growth; our ability to attract and retain key personnel; changes in our business
strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general
economic and market conditions. Except as required by applicable law, we undertake no obligation to revise or update any of our
forward-looking statements in order to reflect any event or circumstance that may arise after the date hereof.
For more information, contact: